ARTICLE | Clinical News
Alkermes starts Phase III ENLIGHTEN-Early trial of ALKS 3831
June 15, 2017 8:44 PM UTC
Alkermes plc (NASDAQ:ALKS) began the Phase III ENLIGHTEN-Early trial to evaluate the weight gain profile of samidorphan/olanzapine (ALKS 3831) vs. olanzapine in about 250 young adults with early schizophrenia, schizophreniform or bipolar I disorder. The 12-week, double-blind trial will also evaluate safety of ALKS 3831. Patients will be eligible to receive ALKS 3831 in a 24-month, open-label safety extension...
BCIQ Company Profiles
BCIQ Target Profiles